News | November 28, 2023
Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
The Product will be manufactured at the company's facility in Bengaluru
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
Decision on EU marketing authorisation expected for momelotinib by early 2024
Evinova will operate as a separate health-tech business within AstraZeneca
Subscribe To Our Newsletter & Stay Updated
